The National Institutes of Health (NIH)


Research (R, P, D and U Announcements)

Title (Activity Code) Deadline Announcement Number
Improving oral health and reducing disparities in adolescents (R01) February 5, June 5, October 5 PAR-20-058
Improving oral health and reducing disparities in adolescents (R21) February 16, June 16, October 16 PAR-20-059
National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional) December 5, 2019; February 10, 2020 RFA-DE-20-005
NIDCR Small Grant Program for New Investigators (R03) February 16, June 16, October 16 PAR-19-370
Analytical and/or Clinical Validation of a Candidate Biomarker for Pain March 12, 2020 RFA-NS-18-046
Collaborative Program Grant for Multidisciplinary Teams (RM1) January 25, 2020; May 25, 2020 PAR-17-340
Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) September 25, 2020; September 25, 2021 PAR-19-259
NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) May 18, 2020; May 20, 2021 PAR-19-204
Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42) September 5, January 5, April 5 PA-19-021
Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44) September 5, January 5, April 5 PA-19-022
Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42) September 5, January 5, April 5 PA-19-075
Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44) September 5, January 5, April 5 PA-19-076
NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03) February 16, June 16, October 16 PAR-19-145
Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01) February 5, June 5, October 5 PAR-19-292
Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21) February 16, June 16, October 16 PAR-19-293
Basic and Translational Oral Health Research Related to HIV/AIDS (R01/ R21) May 7, September 7, January 7 PA-18-699, PA-18-695
NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01) February 12, June 12, October 12 PAR-18-359
Precision Imaging of Oral Lesions (R01/R21) R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16 PAR-18-787 (R01)/PAR-18-788 (R21)
NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) February 6, June 8, and October 6 of 2020 PAR-18-547
Discovery of Biomarkers, Biomarker Signatures, and endpoints for Pain (R61/R33) March 12, 2020 RFA-NS-18-041
Administrative Supplements for Research on Dietary Supplements (Admin Supp) January 15, April 15 and October 15 PA-18-817
HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) February 21, June 22, October 21, 2020; February 21, 2021 by 5:00 PM RFA-NS-19-018
Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21) June 27 and October 24 PAR-18-847
Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01/R21) R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16 PA-18-874
Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) R01: February 5, June 5, October 5 PA-18-876
Clinical Research to Improve the Oral Health of Older Adults (R21) October 16, February 16, June 16 PAR-19-240
Clinical Research to Improve the Oral Health of Older Adults (R01) October 5, February 5, June 5 PAR-19-239
Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Career Enhancement Award) October 12, February 12, June 12 PAR-19-238
NIDCR Prospective Observational or Biomarker Clinical Validation Study Cooperative Agreement (U01) October 5, February 5, June 5 PAR-17-154

Training (K Announcements)

Title (Activity Code) Deadline Announcement Number
Mentored Clinical Scientist Research Career Development Award (K08) February 12, June 12, October 12 PA-19-117
Midcareer Investigator Award in Patient-Oriented Research (K24) February 12, June 12, October 12 PA-19-122
Mentored Patient-Oriented Research Career Development Award (K23) February 12, June 12, October 12 PA-19-119
NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) February 12, June 12, October 12 PAR-19-144

Research (R, P, D and U Announcements)


Title: Improving oral health and reducing disparities in adolescents (R01)
Announcement Number: PAR-20-058
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2023


Title: Improving oral health and reducing disparities in adolescents (R21)
Announcement Number: PAR-20-059
Deadline: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2023


Title: National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)
Announcement Number: RFA-DE-20-005
Deadline: December 5, 2019; February 10, 2020
Purpose: The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase, with a combined total funding period of up to six years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, consideration of the dental PBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds.
The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.
Award: The UG3 phase is limited to a total of $275,000 in direct costs over the entire UG3 phase. If awarded, the UH3 phase is limited to a total of $1,600,000 in direct costs over the entire UH3 phase. Application budgets need to reflect the actual needs of the proposed project. The maximum period of the combined UG3 and UH3 phases is 6 years, with a maximum of 2 years for the UG3 phase and a maximum of 4 or 5 years for the UH3 phase, depending upon the length of the UG3 phase. The entire project must be completed by May 31, 2026.
Eligibility & Guidelines: Here
Announcement Expires:  February 11, 2020


Title: NIDCR Small Grant Program for New Investigators (R03)
Announcement Number: PAR-19-370
Deadline: February 16, June 16, October 16
Purpose: The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.
Award: A budget for direct costs of up to $200,000 may be requested. Application budgets should not exceed $100,000 in direct costs in either year.
Eligibility & Guidelines: Here
Announcement Expires:  September 8, 2022


Title: Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)
Announcement Number: RFA-NS-18-046
Deadline: March 12, 2020 by 5:00 PM
Purpose: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice.
NIDCR is interested in analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints for painful disorders of the orofacial region including temporomandibular joint disorders, trigeminal neuropathies, burning mouth syndrome, oral cancer pain, dental pain, and other conditions. Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  March 13, 2020


Title: Collaborative Program Grant for Multidisciplinary Teams (RM1)
Announcement Number: PAR-17-340
Deadline: January 25, 2020; May 25, 2020
Purpose: Many research questions in biomedical science can be pursued by single investigators and their close collaborators and are adequately supported by individual and multiple PD/PI research grants. However, the scope of some scientific problems is beyond the capabilities of a small group of investigators. Such complex and challenging research questions benefit from the integrated efforts of teams of research laboratories employing complementary approaches and having diverse areas of intellectual and technical expertise, and the necessary resources to accomplish a unified scientific goal. Such team-based efforts can produce convergent, lasting scientific benefits with high impact, such as the creation of new disciplines of study, resolution of long standing or intractable problems, or definition of new areas that challenge current paradigms.
This funding opportunity announcement (FOA) encourages Collaborative Program Grant applications from institutions/organizations that propose to conduct research to address complex and challenging biomedical problems, important for the mission of NIGMS, through deeply integrated, multidisciplinary research teams. The Collaborative Program Grant is designed to support research in which funding a team of interdependent investigators offers significant advantages over support of individual research project grants. Applications should address critical issues and be sufficiently challenging, ambitious, and innovative that objectives could not be achieved by individual investigators.
Award: While applications may request research program budgets of up to $1.5 million direct costs per year, it is anticipated that most awards will be between $700,000-$900,000 direct costs. Inflationary adjustments are not allowed. The requested budget should be consistent with the number of PDs/PIs and the complexity and needs of the proposed program. In addition to the research program budget, an additional $250,000 direct costs per year may be requested for optional exploratory pilot studies for ESIs. Applications may request up to five years of support.
Eligibility & Guidelines: Here


Title: Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
Announcement Number: PAR-19-204
Deadline: May 18, 2020; May 20, 2021
Purpose: The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research at U.S. institutions. Each CEGS award supports a multi-investigator, interdisciplinary team to develop transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomic science at its institution by facilitating the interaction of investigators from several disciplines. By training new and experienced investigators it will expand the pool of genomics scientists and engineers.
Award: Applicants may request up to $1.75 million direct costs for any year for continuing operations (e.g., personnel, standard laboratory equipment, supplies, travel, consortia, and other expenses). Inflationary adjustments will not be allowed. Many applications will not need to request the maximum budget and the size and duration of the awards will vary because the nature and scope of the research programs will vary. Because of the unusual nature of these Centers, there may be a need to acquire specialized equipment. Funds for such specialized equipment may be requested in excess of the $1.75 million limit if well justified, although funds above $500,000 over the life of the grant will generally not be permitted. A CEGS application may request up to five years of support. The maximum length of support for a Center under this program (with a renewal) is ten years.
Eligibility & Guidelines: Here


Title: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
Announcement Number: PAR-19-259
Deadline: September 25, 2020; September 25, 2021
Purpose: This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.
Award: Application budgets for direct costs cannot exceed $10,000,000 for the entire 5 year project period including no cost extensions, but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here


Title: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42)
Announcement Number: PA-19-021
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires:  September 6, 2021


Title: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44)
Announcement Number: PA-19-022
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project
Eligibility & Guidelines: Here
Announcement Expires:  September 6, 2021


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42)
Announcement Number: PA-19-075
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires: January 6, 2022


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44)
Announcement Number: PA-19-076
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires: January 6, 2022


Title: NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03)
Announcement Number: PAR-19-145
Deadline: February 16, June 16, October 16
Purpose: The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.
Award: A budget for direct costs of up to $100,000 per year, with a maximum of $200,000 direct costs over two years, may be requested.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01)
Announcement Number: PAR-19-292
Deadline: February 5, June 5, October 5
Purpose: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21)
Announcement Number: PAR-19-293
Deadline: February 16, June 16, October 16
Purpose: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS , and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
Announcement Number: RFA-NS-19-018
Deadline: February 21, June 22, October 21, 2020; February 21, 2021 by 5:00 PM
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.
This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices’ existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data.
For more information, see https://braininitiative.nih.gov/resources/brain_ppp/index.htm, https://commonfund.nih.gov/sparc/newmarkets, and https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  February 23, 2021


Title: Basic and Translational Oral Health Research Related to HIV/AIDS (R01/ R21)
Announcement Number: PA-18-699, PA-18-695
Deadline: May 7, September 7, January 7
Purpose: This funding opportunity announcement (FOA) encourages innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2021


Title: NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01)
Announcement Number: PAR-18-359
Deadline: February 12, June 12, October 12
Purpose: The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-321).
Award: Award budgets are composed of salary and other program-related expenses, as described below. NIDCR will contribute up to $ 100,000 per year toward the salary of the career award recipient. Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. NIDCR will contribute $25,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Salary for mentors, secretarial and administrative assistants, etc. is not allowed.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2021


Title: Precision Imaging of Oral Lesions (R01/R21)
Announcement Number: PAR-18-787 (R01)/PAR-18-788 (R21)
Deadline: R01: February 5, June 5, October 5 / R21:February 16, June 16, October 16
Purpose: The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.
Award: Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3)
Announcement Number: PAR-18-547
Deadline: February 6, June 8, and October 6 of 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit the Program Director/Principal Investigator to finalize the study team and will support activities to develop: the final clinical protocol; the Clinical Investigator’s Brochure (or equivalent), if needed; the data management system and other tools for data collection and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UG3 planning phase is not designed for pre-clinical studies with animals, the collection of preliminary data on the efficacy of the intervention (such as pilot testing), or the collection of observational data from humans to support the rationale for a clinical trial. Evaluation of the potential subject population to determine individuals’ eligibility for participation in the future UH3 trial is allowed in the UG3 phase but not required. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial.
Award: Application budgets are limited to less than $400,000 in direct costs for the UG3 phase; Application budgets are not limited for the UH3 phase, but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2021


Title: Discovery of Biomarkers, Biomarker Signatures, and endpoints for Pain (R61/R33)
Announcement Number: RFA-NS-18-041
Deadline: March 12, 2020
Purpose: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: March 13, 2020


Title: Administrative Supplements for Research on Dietary Supplements (Admin Supp)
Announcement Number: PA-18-817
Deadline: January 15, April 15 and October 15
Purpose: This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease. This FOA will not support new clinical trials.
Award: Budget requests may be for no more than $100,000 in direct costs. Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.
Eligibility & Guidelines: Here
Announcement Expires: April 16, 2020


Title: Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21)
Announcement Number: PAR-18-847
Deadline: June 27 and October 24
Purpose: The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: June 28, 2020


Title: Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01/R21)
Announcement Number: PA-18-874
Deadline: R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/developmental, investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.
Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01)
Announcement Number: PA-18-876
Deadline: February 5, June 5, October 5
Purpose: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other ‘-omic’ sciences, biotechnology, and bioinformatics.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01)
Announcement Number: PA-18-876
Deadline: February 5, June 5, October 5
Purpose: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other ‘-omic’ sciences, biotechnology, and bioinformatics.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Clinical Research to Improve the Oral Health of Older Adults (R21)
Announcement Number: PAR-19-240
Deadline: February 16, 2020; June 16, 2020; October 16, 2020; February 16, 2021; June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022
AIDS Dates: January 7, 2020; May 7, 2020; September 7, 2020; January 7, 2021; May 7, 2021; September 7, 2021; January 7, 2022; May 7, 2022; September 7, 2022
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.
Award: The combined budget for direct costs for the two-year project period may not exceed $275,000 direct costs. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  September 8, 2022


Title: Clinical Research to Improve the Oral Health of Older Adults (R01)
Announcement Number: PAR-19-239
Deadline: February 5, 2020; June 5, 2020; October 5, 2020; February 5, 2021; June 5, 2021; October 5, 2021; February 5, 2022; June 5, 2022
AIDS Dates: January 7, 2020; May 7, 2020; September 7, 2020; January 7, 2021; May 7, 2021; September 7, 2021; January 7, 2022; May 7, 2022; September 7, 2022
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.
Eligibility & Guidelines: Here
Announcement Expires:  September 7, 2022


Title: Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Career Enhancement Award)
Announcement Number: PAR-19-238
Deadline: February 12, 2020; June 12, 2020; October 12, 2020; February 12, 2021; June 12, 2021; October 12, 2021, February 12, 2022
AIDS Dates: January 7, 2020; May 7, 2020; September 7, 2020; January 7, 2021; May 7, 2021; September 7, 2021; January 7, 2022; May 7, 2022
Purpose: This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Award: Award budgets are composed of salary and other program-related expenses, as described below. A project period from 2.5 months to 12 months may be requested.
Eligibility & Guidelines: Here
Announcement Expires:  May 8, 2022


Title: NIDCR Prospective Observational or Biomarker Clinical Validation Study Cooperative Agreement (U01)
Announcement Number: PAR-17-154
Deadline: February 5, 2020
AIDS Dates: January 7, 2020
Letter of Intent due 30 days prior to the application due date
Purpose: This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous cooperative agreement award from NIDCR.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. A project duration of up to five years may be requested.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2020


Training (K Announcements)

Title: Mentored Clinical Scientist Research Career Development Award (K08)
Announcement Number: PA-19-117
Deadline: February 12, June 12, October 12
Purpose: The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and “protected time” to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-116).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Mentored Patient-Oriented Research Career Development Award (K23)
Announcement Number: PA-19-119
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-118).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Midcareer Investigator Award in Patient-Oriented Research (K24)
Announcement Number: PA-19-122
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-121).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00)
Announcement Number: PAR-19-144
Deadline: February 12, June 12, October 12
Purpose: This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141).
The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022